LIVIVO - Search results -

Search results

Result 1 - 10 of total 1303

Search options

Book ; Online: Medieval Welsh Medical Texts : Volume One: The Recipes

Luft, Diana

2020

Keywords	Medieval history ; Classical texts ; Physicians of Myddfai ; corpus ; medieval medical recipes ; Welsh
Size	1 electronic resource (624 pages)
Document type	Book ; Online
Note	English ; Open Access
HBZ-ID	HT021051623
ISBN	9781786835482 ; 1786835487
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: In memory of Professor Zdzisława Świerczyńska, Ph.D., D.Med.Sc.

Stanisław Luft

Rheumatology, Vol 54, Iss 3, Pp 150-

2016 Volume 150

Keywords	Medicine ; R
Language	English
Publishing date	2016-07-01T00:00:00Z
Publisher	Termedia Publishing House
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Activation of Tripartite Motif Containing 63 Expression by Transcription Factor EB and Transcription Factor Binding to Immunoglobulin Heavy Chain Enhancer 3 Is Regulated by Protein Kinase D and Class IIa Histone Deacetylases.

Pablo Tortola, Cristina / Fielitz, Britta / Li, Yi / Rüdebusch, Julia / Luft, Friedrich C / Fielitz, Jens

Frontiers in physiology

2021 Volume 11, Page(s) 550506

Abstract: Rationale: The ubiquitin-proteasome system (UPS) is responsible for skeletal muscle atrophy. We showed earlier that the transcription factor EB (TFEB) plays a role by increasing E3 ubiquitin ligase muscle really interesting new gene-finger 1(MuRF1)/: ... ...

Abstract	Rationale: The ubiquitin-proteasome system (UPS) is responsible for skeletal muscle atrophy. We showed earlier that the transcription factor EB (TFEB) plays a role by increasing E3 ubiquitin ligase muscle really interesting new gene-finger 1(MuRF1)/ Objective: Because protein kinase D1 (PKD1), histone deacetylase 5 (HDAC5), and TFEB belong to respective families with close structural, regulatory, and functional properties, we hypothesized that these families comprise a network regulating Methods and results: We found that TFEB and transcription factor for immunoglobulin heavy-chain enhancer 3 (TFE3) activate Conclusion: TFEB and TFE3 activate
Language	English
Publishing date	2021-01-13
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2564217-0
ISSN	1664-042X
ISSN	1664-042X
DOI	10.3389/fphys.2020.550506
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Conference proceedings: Durvalumab (D)+/− tremelimumab (T)+chemotherapy (CT) in 1L metastatic (m) NSCLC: overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)

Griesinger, F / Johnson, M / Cho, B / Luft, A / Alatorre-Alexander, J / Geater, S / Laktionov, K / Kim, S / Ursol, G / Hussein, M / Lim, F / Yang, C / Araujo, L / Saito, H / Reinmuth, N / Lai, Z / Mann, H / Shi, X / Peters, S /

Garon, E / Mok, T / Kern, J

Pneumologie

2023 Volume 77, Issue S 01

Event/congress	63. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V., Düsseldorf, 2023-03-29
Language	German
Publishing date	2023-03-01
Publisher	Georg Thieme Verlag
Publishing place	Stuttgart ; New York
Document type	Article ; Conference proceedings
ZDB-ID	607630-0
ISSN	1438-8790 ; 0934-8387
ISSN (online)	1438-8790
ISSN	0934-8387
DOI	10.1055/s-0043-1760883
Database	Thieme publisher's database

In stock of ZB MED Cologne/Königswinter

Uh II Zs.142: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 54: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia.

Radujkovic, Aleksandar / Schnitzler, Paul / Ho, Anthony D / Dreger, Peter / Luft, Thomas

Clinical nutrition (Edinburgh, Scotland)

2017 Volume 36, Issue 2, Page(s) 542–551

Abstract: Background & aims: Azacitidine (AZA) therapy has become the recommended first-line treatment for patients with high-risk myelodysplastic syndromes (MDS) and oligoblastic (<30% bone marrow blasts) acute myeloid leukemia (AML). However, improvement of the ...

Abstract	Background & aims: Azacitidine (AZA) therapy has become the recommended first-line treatment for patients with high-risk myelodysplastic syndromes (MDS) and oligoblastic (<30% bone marrow blasts) acute myeloid leukemia (AML). However, improvement of the efficacy of AZA treatment remains a challenge. We retrospectively tested the hypothesis that VitD levels (25-hydroxyvitamin D3) prior to start of first-line AZA therapy are predictive of overall survival (OS) in patients diagnosed with MDS and secondary oligoblastic AML. Furthermore, the antiproliferative effects of AZA in combination with 25-hydroxyvitamin D3 and 1α,25-dihydroxyvitamin D3 were investigated in vitro. Methods: A total of 58 patients treated at our center between 2006 and 2014 were analyzed. Serum levels of VitD were quantified using a standard, commercially available 25-hydroxyvitamin D3 chemiluminescent immunoassay. Effects on cell proliferation were assessed using tetrazolium-based MTT assays. Results: Median serum VitD level prior to AZA treatment was 32.8 nM (range 11.0-101.5 nM). Patient, disease and treatment characteristics did not differ significantly between the low (≤32.8 nM; n = 29) and high (>32.8 nM; n = 29) VitD group. Estimated probability of 2-year OS in the low versus high VitD group was 14% versus 40% (P < 0.05). In multivariable analysis with OS as endpoint, adverse cytogenetics (HR 2.66, P = 0.03) and VitD (per 10 nM decrease, HR 1.68, P = 0.02) were independent predictors of worse survival. In-vitro treatment of myeloid cell lines with AZA in combination with VitD produced synergistic and additive antiproliferative effects. Addition of nanomolar VitD concentrations to AZA resulted in potentiation of AZA activity. Conversely, combination with the VitD antagonist TEI-9647 resulted in inhibition of AZA activity. Conclusions: Our study suggests that higher VitD levels were associated with a survival advantage following first-line AZA therapy. Enhanced cytotoxic effects upon combination treatment may contribute to the observed clinical effects. VitD repletion/supplementation during AZA treatment should be explored.
Language	English
Publishing date	2017-04
Publishing country	England
Document type	Journal Article
ZDB-ID	604812-2
ISSN	1532-1983 ; 0261-5614
ISSN (online)	1532-1983
ISSN	0261-5614
DOI	10.1016/j.clnu.2016.01.021
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1774: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Perspective on combination RAS blocking therapy: off-TARGET, dis-CORD, MAP-to-nowhere, low ALTITUDE, and NEPHRON-D.

Luft, Friedrich C

American journal of nephrology

2014 Volume 39, Issue 1, Page(s) 46–49

MeSH term(s)	Angiotensin-Converting Enzyme Inhibitors/administration & dosage ; Antihypertensive Agents/administration & dosage ; Blood Pressure ; Clinical Trials as Topic ; Diabetes Complications/drug therapy ; Diabetes Mellitus, Type 2/physiopathology ; Humans ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/drug therapy ; Renin-Angiotensin System/drug effects ; Research Design ; Treatment Outcome
Chemical Substances	Angiotensin-Converting Enzyme Inhibitors ; Antihypertensive Agents
Language	English
Publishing date	2014
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	604540-6
ISSN	1421-9670 ; 0250-8095
ISSN (online)	1421-9670
ISSN	0250-8095
DOI	10.1159/000357593
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1635: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Pretransplant Vitamin D Deficiency Is Associated With Higher Relapse Rates in Patients Allografted for Myeloid Malignancies.

Radujkovic, Aleksandar / Kordelas, Lambros / Krzykalla, Julia / Beelen, Dietrich W / Benner, Axel / Lehners, Nicola / Schmidt, Katharina / Dreger, Peter / Luft, Thomas

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2017 Volume 35, Issue 27, Page(s) 3143–3152

Abstract: Purpose Vitamin D (VitD) deficiency is common in patients with hematologic malignancies undergoing ...

Abstract	Purpose Vitamin D (VitD) deficiency is common in patients with hematologic malignancies undergoing allogeneic transplantation (alloSCT), but its prognostic relevance is unclear. Patients and Methods The impact of pretransplant VitD status on overall survival, relapse mortality, and nonrelapse mortality was investigated retrospectively in a cohort of 492 patients undergoing alloSCT at our center from 2002 to 2013. VitD deficiency was defined as a serum level of 25-hydroxyvitamin D3 < 20 ng/mL (equivalent to < 50 nM) before alloSCT and was assessed using accredited laboratory methods and a standard chemiluminescent immunoassay. Results were validated in an independent cohort of 398 patients diagnosed with myeloid malignancies. Results A total of 396 (80%) and 348 (87%) patients had VitD deficiency before alloSCT in the training and validation cohort, respectively. In the training cohort, VitD deficiency was significantly associated with inferior overall survival (hazard ratio [HR], 1.78; P = .007) in multivariable analysis. This was due to a higher risk of relapse (HR, 1.96; P = .006) rather than nonrelapse mortality. A significant association of pretransplant VitD deficiency with higher relapse rates was observed only in patients diagnosed with myeloid (HR, 2.55; P = .014) but not with lymphatic diseases (HR, 1.60; P = .147). A similar impact of pretransplant VitD deficiency on relapse risk in myeloid diseases was also observed in an independent patient cohort (HR, 2.60; P = .017). Validation of the effect of VitD deficiency on relapse in patients with myeloid malignancies was successful. Conclusion Pretransplant VitD deficiency was associated with a higher risk of relapse in patients allografted for myeloid malignancies. Prospective studies on VitD status and correction of VitD deficiency in the setting of alloSCT are highly warranted.
MeSH term(s)	Female ; Hematologic Neoplasms/mortality ; Hematologic Neoplasms/therapy ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Prognosis ; Retrospective Studies ; Risk Factors ; Survival Rate ; Transplantation, Homologous ; Treatment Outcome ; Vitamin D Deficiency/blood ; Vitamin D Deficiency/complications
Language	English
Publishing date	2017-09-20
Publishing country	United States
Document type	Journal Article
ZDB-ID	604914-x
ISSN	1527-7755 ; 0732-183X
ISSN (online)	1527-7755
ISSN	0732-183X
DOI	10.1200/JCO.2017.73.0085
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1847: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 650: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Online: Graft-versus-Host Erkrankung, chronisch

Wolff, Daniel / Zeiser, Robert / Scheid, Christoph / Luft, Thomas / Mielke, Stephan / Dreger, Peter / Finke, Jürgen / Holler, Ernst / Greinix, Hildegard / Halter, Jörg

Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen

(Onkopedia Leitlinien)

2023

Abstract: Die chronische Graft-versus-Host-Erkrankung (GvHD) ist eine protrahiert einsetzende Reaktion des Spenderimmunsystems gegen Gewebe des Empfängers. Sie tritt bei ca. 50% der Patient*innen nach allogener hämatopoetischer Stammzelltransplantation und in der ... ...

Institution	Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie Schweizerische Gesellschaft für Medizinische Onkologie Schweizerische Gesellschaft für Hämatologie Deutsche Arbeitsgemeinschaft für Hämatopoetische Stammzelltransplantation und Zelluläre Therapie
Author's details	DGHO - Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V., OeGHO - Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie, SSMO/SSOM/SGMO, SGH-SSH ; Autoren: Daniel Wolff, Robert Zeiser, Christof Scheid, Thomas Luft, Stephan Mielke, Peter Dreger, Jürgen Finke, Ernst Holler, Hildegard Greinix, Jörg Halter für die DAG-HSZT, Deutsche Arbeitsgemeinschaft für Hämatopoetische Stammzelltransplantation und Zelluläre Therapie e.V
Series title	Onkopedia Leitlinien
Abstract	Die chronische Graft-versus-Host-Erkrankung (GvHD) ist eine protrahiert einsetzende Reaktion des Spenderimmunsystems gegen Gewebe des Empfängers. Sie tritt bei ca. 50% der Patient*innen nach allogener hämatopoetischer Stammzelltransplantation und in der Regel nach 2 bis 18 Monaten erstmalig auf. Für die Diagnose muss eine eindeutige klinische Symptomatik/Manifestation oder eine histolo gische Sicherung vorliegen. Die Therapie richtet sich nach dem Schweregrad der chronischen GvHD und der Organmanifes tation. Sie besteht aus topischen Maßnahmen, systemischer Gabe von Kortikosteroiden, ggf. in Kombination mit weiteren Immunsuppressiva. Insbesondere die schwere chronischen GvHD ist für ca. 25% der Todesfälle nach allogener hämatopoetischer Stammzelltransplantation mit verantwortlich.
Subject code	610
Language	German
Size	1 Online-Ressource (24 Seiten), Diagramme
Edition	Stand: Januar 2023
Publisher	DGHO - Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V
Publishing place	Berlin
Publishing country	Germany
Document type	Book ; Online
Note	Open Access
HBZ-ID	HT030067760
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article: Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia

Radujkovic, Aleksandar / Paul Schnitzler / Anthony D. Ho / Peter Dreger / Thomas Luft

Clinical nutrition. 2017 Apr., v. 36

2017

Abstract: Azacitidine (AZA) therapy has become the recommended first-line treatment for patients with high-risk myelodysplastic syndromes (MDS) and oligoblastic (<30% bone marrow blasts) acute myeloid leukemia (AML). However, improvement of the efficacy of AZA ... ...

Abstract	Azacitidine (AZA) therapy has become the recommended first-line treatment for patients with high-risk myelodysplastic syndromes (MDS) and oligoblastic (<30% bone marrow blasts) acute myeloid leukemia (AML). However, improvement of the efficacy of AZA treatment remains a challenge. We retrospectively tested the hypothesis that VitD levels (25-hydroxyvitamin D3) prior to start of first-line AZA therapy are predictive of overall survival (OS) in patients diagnosed with MDS and secondary oligoblastic AML. Furthermore, the antiproliferative effects of AZA in combination with 25-hydroxyvitamin D3 and 1Î±,25-dihydroxyvitamin D3 were investigated inÂ vitro.A total of 58 patients treated at our center between 2006 and 2014 were analyzed. Serum levels of VitD were quantified using a standard, commercially available 25-hydroxyvitamin D3 chemiluminescent immunoassay. Effects on cell proliferation were assessed using tetrazolium-based MTT assays.Median serum VitD level prior to AZA treatment was 32.8Â nM (range 11.0â101.5Â nM). Patient, disease and treatment characteristics did not differ significantly between the low (â¤32.8Â nM; nÂ =Â 29) and high (>32.8Â nM; nÂ =Â 29) VitD group. Estimated probability of 2-year OS in the low versus high VitD group was 14% versus 40% (PÂ <Â 0.05). In multivariable analysis with OS as endpoint, adverse cytogenetics (HR 2.66, PÂ =Â 0.03) and VitD (per 10Â nM decrease, HR 1.68, PÂ =Â 0.02) were independent predictors of worse survival. In-vitro treatment of myeloid cell lines with AZA in combination with VitD produced synergistic and additive antiproliferative effects. Addition of nanomolar VitD concentrations to AZA resulted in potentiation of AZA activity. Conversely, combination with the VitD antagonist TEI-9647 resulted in inhibition of AZA activity.Our study suggests that higher VitD levels were associated with a survival advantage following first-line AZA therapy. Enhanced cytotoxic effects upon combination treatment may contribute to the observed clinical effects. VitD repletion/supplementation during AZA treatment should be explored.
Keywords	25-hydroxycholecalciferol ; antagonists ; blood serum ; bone marrow ; cell proliferation ; chemiluminescence ; cytogenetics ; cytotoxicity ; immunoassays ; myeloid leukemia ; patients ; probability ; repletion ; therapeutics
Language	English
Dates of publication	2017-04
Size	p. 542-551.
Publishing place	Elsevier Ltd
Document type	Article
ZDB-ID	604812-2
ISSN	1532-1983 ; 0261-5614
ISSN (online)	1532-1983
ISSN	0261-5614
DOI	10.1016/j.clnu.2016.01.021
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Cologne/Königswinter

Zs.A 1774: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Perspective on Combination RAS Blocking Therapy: Off-TARGET, Dis-CORD, MAP-to-Nowhere, Low ALTITUDE, and NEPHRON-D

Luft, Friedrich C.

American Journal of Nephrology

2014 Volume 39, Issue 1, Page(s) 46–49

Institution	Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Medical Faculty of the Charité, Berlin, Germany; Department of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tenn., USA
Keywords	trials ; cardiovascular ; hypertension ; kidney
Language	English
Publishing date	2014-01-15
Publisher	S. Karger AG
Publishing place	Basel, Switzerland
Document type	Article
Note	Future Perspectives
ZDB-ID	604540-6
ISSN	1421-9670 ; 0250-8095
ISSN (online)	1421-9670
ISSN	0250-8095
DOI	10.1159/000357593
Database	Karger publisher's database

In stock of ZB MED Cologne/Königswinter

Zs.A 1635: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito